Xeris Operating Income from 2010 to 2024

XERS Stock

USD 3.51 0.07 1.96%

Xeris Pharmaceuticals Operating Income yearly trend continues to be comparatively stable with very little volatility. Operating Income will likely drop to about -46.2 M in 2024. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Xeris Pharmaceuticals generates from its operations. View All Fundamentals

Operating Income

First Reported

2016-12-31

Previous Quarter

-8.2 M

Current Value

-12.9 M

Quarterly Volatility

9.9 M

Covid

Check Xeris Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Xeris Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 5 M, Depreciation And Amortization of 13.8 M or Interest Expense of 27.9 M, as well as many indicators such as Price To Sales Ratio of 1.88, Dividend Yield of 0.0 or Days Sales Outstanding of 154. Xeris financial statements analysis is a perfect complement when working with Xeris Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Xeris Pharmaceuticals Correlation against competitors.

For more information on how to buy Xeris Stock please use our How to Invest in Xeris Pharmaceuticals guide.

Latest Xeris Pharmaceuticals' Operating Income Growth Pattern

Below is the plot of the Operating Income of Xeris Pharmaceuticals over the last few years. Operating Income is the amount of profit realized from Xeris Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Xeris Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Xeris Pharmaceuticals' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Xeris Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Xeris Operating Income Regression Statistics

	Arithmetic Mean	(42,574,433)
	Coefficient Of Variation	(83.58)
	Mean Deviation	29,513,262
	Median	(26,629,000)
	Standard Deviation	35,581,807
	Sample Variance	1266.1T
	Range	109.1M
	R-Value	(0.68)
	Mean Square Error	737.7T
	R-Squared	0.46
	Significance	0.01
	Slope	(5,390,241)
	Total Sum of Squares	17724.9T

Xeris Operating Income History

	2024	-46.2 M
	2023	-44 M
	2021	-81.9 M
	2020	-83.5 M
	2019	-122.4 M
	2018	-59.3 M
	2017	-26.6 M

Other Fundumenentals of Xeris Pharmaceuticals

Non Operating Income Net Other

Xeris Pharmaceuticals Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Capital Surpluse	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Invested Capital	Net Working Capital	Long Term Debt	Short Term Investments	Long Term Debt Total	Capital Stock	Deferred Long Term Liab	Intangible Assets
Total Assets		0.66	-0.42	0.84	0.83	-0.95	0.77	0.84	0.89	0.96	0.95	0.36	0.92	0.85	0.95	0.6	0.89	-0.77	0.92	0.97	0.92	0.45
Total Stockholder Equity	0.66		0.36	0.53	0.43	-0.56	0.28	0.35	0.69	0.41	0.8	0.64	0.46	0.53	0.81	0.84	0.42	-0.25	0.56	0.47	0.53	-0.01
Net Tangible Assets	-0.42	0.36		-0.3	-0.43	0.45	-0.51	-0.6	-0.19	-0.63	-0.17	0.29	-0.57	-0.35	-0.18	0.23	-0.55	0.73	-0.33	-0.58	-0.39	-0.47
Current Deferred Revenue	0.84	0.53	-0.3		0.92	-0.94	0.86	0.83	0.95	0.8	0.86	0.18	0.87	0.97	0.87	0.61	0.83	-0.65	0.93	0.83	0.84	0.57
Net Debt	0.83	0.43	-0.43	0.92		-0.96	0.96	0.96	0.93	0.82	0.81	0.32	0.95	0.96	0.84	0.54	0.87	-0.8	0.86	0.87	0.81	0.82
Retained Earnings	-0.95	-0.56	0.45	-0.94	-0.96		-0.9	-0.93	-0.96	-0.92	-0.92	-0.32	-0.98	-0.95	-0.93	-0.61	-0.91	0.8	-0.93	-0.95	-0.9	-0.64
Accounts Payable	0.77	0.28	-0.51	0.86	0.96	-0.9		0.9	0.84	0.8	0.7	0.22	0.91	0.89	0.73	0.31	0.76	-0.79	0.77	0.83	0.71	0.83
Net Receivables	0.84	0.35	-0.6	0.83	0.96	-0.93	0.9		0.85	0.85	0.76	0.36	0.96	0.91	0.8	0.49	0.92	-0.91	0.79	0.9	0.78	0.82
Capital Surpluse	0.89	0.69	-0.19	0.95	0.93	-0.96	0.84	0.85		0.8	0.94	0.43	0.9	0.96	0.95	0.76	0.83	-0.66	0.92	0.85	0.86	0.59
Total Liab	0.96	0.41	-0.63	0.8	0.82	-0.92	0.8	0.85	0.8		0.84	0.18	0.92	0.81	0.84	0.4	0.91	-0.82	0.9	0.99	0.9	0.52
Total Current Assets	0.95	0.8	-0.17	0.86	0.81	-0.92	0.7	0.76	0.94	0.84		0.47	0.86	0.85	0.99	0.8	0.82	-0.61	0.91	0.87	0.9	0.38
Short Term Debt	0.36	0.64	0.29	0.18	0.32	-0.32	0.22	0.36	0.43	0.18	0.47		0.3	0.33	0.52	0.61	0.28	-0.3	0.17	0.24	0.18	0.3
Common Stock	0.92	0.46	-0.57	0.87	0.95	-0.98	0.91	0.96	0.9	0.92	0.86	0.3		0.91	0.87	0.52	0.9	-0.86	0.87	0.95	0.87	0.71
Property Plant Equipment	0.85	0.53	-0.35	0.97	0.96	-0.95	0.89	0.91	0.96	0.81	0.85	0.33	0.91		0.89	0.64	0.88	-0.76	0.89	0.85	0.8	0.68
Net Invested Capital	0.95	0.81	-0.18	0.87	0.84	-0.93	0.73	0.8	0.95	0.84	0.99	0.52	0.87	0.89		0.79	0.85	-0.68	0.9	0.87	0.86	0.43
Net Working Capital	0.6	0.84	0.23	0.61	0.54	-0.61	0.31	0.49	0.76	0.4	0.8	0.61	0.52	0.64	0.79		0.55	-0.26	0.61	0.47	0.62	0.18
Long Term Debt	0.89	0.42	-0.55	0.83	0.87	-0.91	0.76	0.92	0.83	0.91	0.82	0.28	0.9	0.88	0.85	0.55		-0.83	0.89	0.94	0.88	0.62
Short Term Investments	-0.77	-0.25	0.73	-0.65	-0.8	0.8	-0.79	-0.91	-0.66	-0.82	-0.61	-0.3	-0.86	-0.76	-0.68	-0.26	-0.83		-0.61	-0.83	-0.59	-0.69
Long Term Debt Total	0.92	0.56	-0.33	0.93	0.86	-0.93	0.77	0.79	0.92	0.9	0.91	0.17	0.87	0.89	0.9	0.61	0.89	-0.61		0.92	0.97	0.47
Capital Stock	0.97	0.47	-0.58	0.83	0.87	-0.95	0.83	0.9	0.85	0.99	0.87	0.24	0.95	0.85	0.87	0.47	0.94	-0.83	0.92		0.93	0.58
Deferred Long Term Liab	0.92	0.53	-0.39	0.84	0.81	-0.9	0.71	0.78	0.86	0.9	0.9	0.18	0.87	0.8	0.86	0.62	0.88	-0.59	0.97	0.93		0.46
Intangible Assets	0.45	-0.01	-0.47	0.57	0.82	-0.64	0.83	0.82	0.59	0.52	0.38	0.3	0.71	0.68	0.43	0.18	0.62	-0.69	0.47	0.58	0.46

Click cells to compare fundamentals

About Xeris Pharmaceuticals Financial Statements

Xeris Pharmaceuticals shareholders use historical fundamental indicators, such as Operating Income, to determine how well the company is positioned to perform in the future. Although Xeris Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Xeris Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Xeris Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Operating Income	-44 M	-46.2 M
Non Operating Income Net Other	-6.9 M	-7.3 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Xeris Stock Analysis

When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Xeris Operating Income from 2010 to 2024

Latest Xeris Pharmaceuticals' Operating Income Growth Pattern

Xeris Operating Income Regression Statistics

Xeris Operating Income History

Other Fundumenentals of Xeris Pharmaceuticals

Xeris Pharmaceuticals Operating Income component correlations

About Xeris Pharmaceuticals Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Xeris Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY